Global Fund PSD advocates for increased funding from U.S. Congress
In advance of the 6th Global Fund Replenishment Conference this October in Lyon, France, PSD representatives visited with nine Congressional offices last month, most of which represent key appropriators in the House of Representatives and Senate, to advocate for an increased pledge to the Global Fund by the U.S. government.
In their meetings, participants highlighted the impactful results that the Global Fund to Fight AIDS, Tuberculosis and Malaria is able to achieve, primarily through its strong partnerships, including with the business community. This replenishment represents an inflection point for the Global Fund, and PSD representatives made it clear to Congress that now is the time to end the three diseases or risk backsliding into disease resurgence. Members of Congress and their staff were urged to increase funding to the Global Fund for fiscal year 2020 to signal strong U.S. commitment to the cause, hopefully catalyzing other donors to follow suit.
Earlier this month, the PSD also signed a joint letter to Congress that reiterated the importance of an increased pledge by the United States. The 21 companies that signed the letter, including leaders in the pharmaceutical, technology and transportation industries, called for US$1.56 billion to be appropriated for the Global Fund in fiscal year 2020 to help “save millions of lives, drive the generosity of other donors and help achieve the full Global Fund Replenishment target.” This is the first joint letter of its kind from the private sector.
Both the advocacy day on Capitol Hill and the joint letter were coordinated by GBCHealth, which serves as Focal Point to the PSD, in partnership with Washington D.C.-based Friends of the Global Fight, an advocacy organization dedicated to sustaining and expanding U.S. support for the Global Fund.
As the primary mechanism by which the private sector contributes to the governance of the Global Fund Board, the PSD is a group of 21 companies that plays a critical role in shaping Global Fund policies and strategies so that they are more effective, impactful and transparent. In light of the Global Fund’s upcoming sixth replenishment, representatives from PSD companies have recently been participating in advocacy efforts on behalf of the Global Fund.
New PSD leadership:
The 41st meeting of the Global Fund Board will take place in Geneva, Switzerland on 15 and 16 May 2019. The meeting will be preceded by briefings on 14 May. Topics and decisions will focus on important issues associated with the upcoming replenishment, including adjustments to the allocation methodology, funding levels for catalytic investments, domestic resource mobilization forecasts, and amendments to the Policy on Restricted Financial Contributions. Similarly, the Board will discuss how to continue streamlining integration of health system strengthening with grant funding.
|Paul Schaper||Sherwin Charles|
At the close of the meeting, the newly elected PSD Board and Alternate Board members will step into their new positions for the upcoming 2019-2021 term. Sherwin Charles, Co-Founder and Chief Executive Officer of Goodbye Malaria, was recently elected as the Global Fund Board member representing the private sector. He helped the international restaurant group Nando’s become one of the first African corporations to contribute to the Global Fund, and has spearheaded a number of discussions on innovative finance with the Fund. Mr. Charles currently serves as Alternate Board member.
Paul Schaper, Executive Director of Global Public Policy at Merck & Co., Inc., was elected Alternate Board member. He has a long history of contributions to the Global Fund, having served previously as both Board and Alternate Board member representing the private sector. Mr. Schaper is responsible for global health policy issues in infectious disease, non-communicable disease and reproductive health at Merck. His work has involved HIV prevention and treatment issues for over two decades.
GBCHealth reconfirmed as Focal Point to the PSD
GBCHealth is pleased to announce that it has been reconfirmed as Focal Point to the PSD until 2022. Through this important partnership GBCHealth has provided support to private sector members in their interactions and engagement with the Global Fund Board, Secretariat and other related stakeholders over the last 12 years. The Focal Point Team, located in the U.S. and Switzerland, is pleased to continue serving the PSD and looks forward to co-creating and leading new and impactful initiatives with private sector partners regarding governance, advocacy, supply chain management and health financing. For more information about the PSD or its activities, please contact Daniel Mora-Brito, Focal Point for the PSD, at email@example.com.